Benign Prostate Hyperplasia (BPH) Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and phosphodiesterase-5 inhibitors), By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, Laser Surgery, Transurethral Microwave Technique (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), and Others), By End User (Hospitals & Clinics, , Ambulatory Surgical Centers, and Others), By Region
Global Benign Prostate Hyperplasia (BPH) Treatment Market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing prevalence of benign prostatic hyperplasia rising global male geriatric population, rise in urological disorders associated with BPH. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which Prostate Cancer was the most prevalent type of cancer, accounting for 14,14,259 cases 2020. Additionally, the lack of awareness among the public for early prostate diagnosis and detection is further expected to drive the growth of the Benign Prostate Hyperplasia (BPH) Treatment Market.
The growing prevalence of fatal diseases has significantly increased the demand for different types of drugs and surgeries. Additionally, expansion in research & development activities being initiated by various governments, ambulatory surgical centers, and pharmaceutical companies across the globe is further expected to create opportunities for the growth of the Benign Prostate Hyperplasia (BPH) Treatment market in the coming years. According to Statista Research Department, as of now, the United States will be the leading country worldwide in terms of spending on research and development, with expenditure exceeding around USD679.4 billion.
According to the Cancer fact sheet, the cancer rates are highest in Australia/New Zealand and North America. Prostate cancer is the fourth most common cancer overall and the second most common cancer in men.
Product Launches Boost Market
Surgery is a superior alternative to treating BPH with medicine; however, due to the post-operative harm that surgical cuts and burns do to the body, patients tend to choose medication. Patients' perceptions have changed as a result of the development of minimally invasive techniques and surgical equipment makers now have a competitive advantage. For instance, Teleflex Inc. launched the UroLift improved tissue control system in August 2020 to treat BPH. To open the urethra, small implants that keep the prostate lobes in their retracted posture might be placed into the system. Patients with challenging prostatic anatomy, such as those who have large lateral lobes or an obstructive median lobe, are the target population for the device. These product launches are anticipated to boost the growth of the market.
Growth in Research & Development
Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel drug/surgery for the treatment of different life-threatening diseases like prostate cancer. According to Clinicaltrials.gov, 17 clinical trials are in different phases of development across the globe for Benign Prostate Hyperplasia (BPH) Treatment. This clearly indicates that a lot of R&D is being done across the globe for developing Benign Prostate Hyperplasia (BPH) Treatment., thereby supporting the growth of the market. However, in February 2017, The Centre for Integrative Oncology (CIO) was established as a joint venture of the All India Institute of Ayurveda (AIIA) and the National Institute of Cancer Prevention and Research (NICPR-ICMR) with the intention of collaborative research activities in cancer.
Rising Investment in Healthcare
Advanced surgical therapies are very expensive; therefore, financial assistance is provided by the government for cancer treatment. An establishment of Ayushman
Bharat Health and Wellness Centers (AB-HWCs) were announced by the Government of India in February 2018 for the diagnosis and screening of three common cancers, i.e., oral, breast, and cervical. Another initiative launched in 2018, namely Pradhan Mantri Jan Arogya Yojana, surged treatment facilities for cancer up to a certain expenditure as per their norms. The chemotherapy and radiotherapy packages, along with surgical oncology, are covered as part of cancer treatment in the impaneled hospitals under the scheme, and a total of 435 procedures have been defined for the treatment of cancer.
Market Segmentation
The Global Benign Prostate Hyperplasia (BPH) Treatment Market can be segmented based on drug treatment, surgical treatment, end user, region, and competitional landscape. Based on drug treatment, the market can be categorized into alpha-blockers, 5-alpha reductase inhibitors, and Phosphodiesterase-5 Inhibitors. Based on surgical treatment, the market can be fragmented into transurethral resection of the prostate (TURP), prostatic urethral lift (PUL), Prostatectomy, laser surgery, transurethral microwave Technique (TUMT), transurethral needle ablation of the prostate (TUNA), and others. Based on end users, the market can be grouped into hospitals and clinics, ambulatory surgical centers, and others.
Company Profiles
Boston Scientific Corporation, Coloplast Corporation, Teleflex Incorporated, Olympus Corporation, Glaxo Smith Kline PLC, Eli Lily, Abbott Laboratories, Medifocus Inc., Urologix, LLC, and Pfizer Inc. are some of the key players operating in the Global Benign Prostate Hyperplasia (BPH) Treatment market.
Report Scope:
In this report, Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Benign Prostate Hyperplasia (BPH) Treatment market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
The growing prevalence of fatal diseases has significantly increased the demand for different types of drugs and surgeries. Additionally, expansion in research & development activities being initiated by various governments, ambulatory surgical centers, and pharmaceutical companies across the globe is further expected to create opportunities for the growth of the Benign Prostate Hyperplasia (BPH) Treatment market in the coming years. According to Statista Research Department, as of now, the United States will be the leading country worldwide in terms of spending on research and development, with expenditure exceeding around USD679.4 billion.
According to the Cancer fact sheet, the cancer rates are highest in Australia/New Zealand and North America. Prostate cancer is the fourth most common cancer overall and the second most common cancer in men.
Product Launches Boost Market
Surgery is a superior alternative to treating BPH with medicine; however, due to the post-operative harm that surgical cuts and burns do to the body, patients tend to choose medication. Patients' perceptions have changed as a result of the development of minimally invasive techniques and surgical equipment makers now have a competitive advantage. For instance, Teleflex Inc. launched the UroLift improved tissue control system in August 2020 to treat BPH. To open the urethra, small implants that keep the prostate lobes in their retracted posture might be placed into the system. Patients with challenging prostatic anatomy, such as those who have large lateral lobes or an obstructive median lobe, are the target population for the device. These product launches are anticipated to boost the growth of the market.
Growth in Research & Development
Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel drug/surgery for the treatment of different life-threatening diseases like prostate cancer. According to Clinicaltrials.gov, 17 clinical trials are in different phases of development across the globe for Benign Prostate Hyperplasia (BPH) Treatment. This clearly indicates that a lot of R&D is being done across the globe for developing Benign Prostate Hyperplasia (BPH) Treatment., thereby supporting the growth of the market. However, in February 2017, The Centre for Integrative Oncology (CIO) was established as a joint venture of the All India Institute of Ayurveda (AIIA) and the National Institute of Cancer Prevention and Research (NICPR-ICMR) with the intention of collaborative research activities in cancer.
Rising Investment in Healthcare
Advanced surgical therapies are very expensive; therefore, financial assistance is provided by the government for cancer treatment. An establishment of Ayushman
Bharat Health and Wellness Centers (AB-HWCs) were announced by the Government of India in February 2018 for the diagnosis and screening of three common cancers, i.e., oral, breast, and cervical. Another initiative launched in 2018, namely Pradhan Mantri Jan Arogya Yojana, surged treatment facilities for cancer up to a certain expenditure as per their norms. The chemotherapy and radiotherapy packages, along with surgical oncology, are covered as part of cancer treatment in the impaneled hospitals under the scheme, and a total of 435 procedures have been defined for the treatment of cancer.
Market Segmentation
The Global Benign Prostate Hyperplasia (BPH) Treatment Market can be segmented based on drug treatment, surgical treatment, end user, region, and competitional landscape. Based on drug treatment, the market can be categorized into alpha-blockers, 5-alpha reductase inhibitors, and Phosphodiesterase-5 Inhibitors. Based on surgical treatment, the market can be fragmented into transurethral resection of the prostate (TURP), prostatic urethral lift (PUL), Prostatectomy, laser surgery, transurethral microwave Technique (TUMT), transurethral needle ablation of the prostate (TUNA), and others. Based on end users, the market can be grouped into hospitals and clinics, ambulatory surgical centers, and others.
Company Profiles
Boston Scientific Corporation, Coloplast Corporation, Teleflex Incorporated, Olympus Corporation, Glaxo Smith Kline PLC, Eli Lily, Abbott Laboratories, Medifocus Inc., Urologix, LLC, and Pfizer Inc. are some of the key players operating in the Global Benign Prostate Hyperplasia (BPH) Treatment market.
Report Scope:
In this report, Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Benign Prostate Hyperplasia (BPH) Treatment Market, By Drug Treatment:
- Alpha Blockers
- 5-Alpha Reductase Inhibitors
- Phosphodiesterase-5 inhibitors
- Benign Prostate Hyperplasia (BPH) Treatment Market, By Surgical Treatment:
- Transurethral resection of the prostate (TURP)
- Prostatic Urethral Lift (PUL)
- Prostatectomy
- Laser surgery
- Transurethral microwave Technique (TUMT)
- Transurethral needle ablation of the prostate (TUNA)
- Others
- Benign Prostate Hyperplasia (BPH) Treatment Market, By End User:
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- Benign Prostate Hyperplasia (BPH) Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in Global Benign Prostate Hyperplasia (BPH) Treatment market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL BPH DEVICES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors)
5.2.2. By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT), Transurethral needle ablation of the prostate (TUNA), and others (Rezum therapy, Urolift therapy, etc)
5.2.3. By End User (hospitals and clinics, ambulatory surgical centres, and Others)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Drug Treatment
5.3.2. By Surgical Treatment
5.3.3. By End User
5.3.4. By Region
6. NORTH AMERICA BPH DEVICES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Treatment
6.2.2. By Surgical Treatment
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States BPH Devices Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Treatment
6.3.1.2.2. By Surgical Treatment
6.3.1.2.3. By End User
6.3.2. Canada BPH Devices Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Treatment
6.3.2.2.2. By Surgical Treatment
6.3.2.2.3. By End User
6.3.3. Mexico BPH Devices Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Treatment
6.3.3.2.2. By Surgical Treatment
6.3.3.2.3. By End User
7. EUROPE BPH TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Treatment
7.2.2. By Surgical Treatment
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France BPH Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Treatment
7.3.1.2.2. By Surgical Treatment
7.3.1.2.3. By End User
7.3.2. Germany BPH Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Treatment
7.3.2.2.2. By Surgical Treatment
7.3.2.2.3. By End User
7.3.3. United Kingdom BPH Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Treatment
7.3.3.2.2. By Surgical Treatment
7.3.3.2.3. By End User
7.3.4. Italy BPH Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Treatment
7.3.4.2.2. By Surgical Treatment
7.3.4.2.3. By End User
7.3.5. Spain BPH Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Treatment
7.3.5.2.2. By Surgical Treatment
7.3.5.2.3. By End User
8. ASIA-PACIFIC BPH TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Treatment
8.2.2. By Surgical Treatment
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China BPH Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Treatment
8.3.1.2.2. By Surgical Treatment
8.3.1.2.3. By End User
8.3.2. Japan BPH Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Treatment
8.3.2.2.2. By Surgical Treatment
8.3.2.2.3. By End User
8.3.3. India BPH Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Treatment
8.3.3.2.2. By Surgical Treatment
8.3.3.2.3. By End User
8.3.4. South Korea BPH Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Treatment
8.3.4.2.2. By Surgical Treatment
8.3.4.2.3. By End User
8.3.5. Australia BPH Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Treatment
8.3.5.2.2. By Surgical Treatment
8.3.5.2.3. By End User
9. SOUTH AMERICA BPH TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Treatment
9.2.2. By Surgical Treatment
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil BPH Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Treatment
9.3.1.2.2. By Surgical Treatment
9.3.1.2.3. By End User
9.3.2. Argentina BPH Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Treatment
9.3.2.2.2. By Surgical Treatment
9.3.2.2.3. By End User
9.3.3. Colombia BPH Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Treatment
9.3.3.2.2. By Surgical Treatment
9.3.3.2.3. By End User
10. MIDDLE EAST AND AFRICA BPH TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Treatment
10.2.2. By Surgical Treatment
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. UAE BPH Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Treatment
10.3.1.2.2. By Surgical Treatment
10.3.1.2.3. By End User
10.3.2. Saudi Arabia BPH Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Treatment
10.3.2.2.2. By Surgical Treatment
10.3.2.2.3. By End User
10.3.3. South Africa BPH Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Treatment
10.3.3.2.2. By Surgical Treatment
10.3.3.2.3. By End User
10.3.4. Turkey BPH Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Drug Treatment
10.3.4.2.2. By Surgical Treatment
10.3.4.2.3. By End User
10.3.5. Egypt BPH Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Drug Treatment
10.3.5.2.2. By Surgical Treatment
10.3.5.2.3. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.1.1. Increasing prevalence of Benign Prostate Hyperplasia
11.1.2. Growing geriatric population
11.1.3. Technological Advancement
11.2. Challenges
11.2.1. High Cost of Procedure
11.2.2. Side effects associated with the technique
11.2.3. Lack of Skilled Professionals to conduct invasive surgeries
12. MARKET TRENDS & DEVELOPMENTS
12.1. Development of new drugs
12.2. Development of new surgeries
13. CLINICAL TRIAL ANALYSIS
13.1. Ongoing Clinical Trials
13.2. Completed Clinical Trials
13.3. Terminated Clinical Trials
13.4. Breakdown of Pipeline, By Development Phase
13.5. Breakdown of Pipeline, By Status
13.6. Breakdown of Pipeline, By Study Type
13.7. Breakdown of Pipeline, By Region
13.8. Clinical Trials Heat Map
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (In Case of Listed Companies)
14.5. Key Personnel
14.5.1. Boston Scientific Corporation
14.5.2. Coloplast Corporation
14.5.3. Teleflex Incorporated
14.5.4. Olympus Corporation
14.5.5. Glaxo Smith Kline PLC
14.5.6. Eli Lily
14.5.7. Abott Laboratories
14.5.8. Medifocus Inc.
14.5.9. Urologix, LLC
14.5.10. Pfizer Inc
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US AND DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL BPH DEVICES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors)
5.2.2. By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT), Transurethral needle ablation of the prostate (TUNA), and others (Rezum therapy, Urolift therapy, etc)
5.2.3. By End User (hospitals and clinics, ambulatory surgical centres, and Others)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Drug Treatment
5.3.2. By Surgical Treatment
5.3.3. By End User
5.3.4. By Region
6. NORTH AMERICA BPH DEVICES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Treatment
6.2.2. By Surgical Treatment
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States BPH Devices Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Treatment
6.3.1.2.2. By Surgical Treatment
6.3.1.2.3. By End User
6.3.2. Canada BPH Devices Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Treatment
6.3.2.2.2. By Surgical Treatment
6.3.2.2.3. By End User
6.3.3. Mexico BPH Devices Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Treatment
6.3.3.2.2. By Surgical Treatment
6.3.3.2.3. By End User
7. EUROPE BPH TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Treatment
7.2.2. By Surgical Treatment
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France BPH Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Treatment
7.3.1.2.2. By Surgical Treatment
7.3.1.2.3. By End User
7.3.2. Germany BPH Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Treatment
7.3.2.2.2. By Surgical Treatment
7.3.2.2.3. By End User
7.3.3. United Kingdom BPH Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Treatment
7.3.3.2.2. By Surgical Treatment
7.3.3.2.3. By End User
7.3.4. Italy BPH Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Treatment
7.3.4.2.2. By Surgical Treatment
7.3.4.2.3. By End User
7.3.5. Spain BPH Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Treatment
7.3.5.2.2. By Surgical Treatment
7.3.5.2.3. By End User
8. ASIA-PACIFIC BPH TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Treatment
8.2.2. By Surgical Treatment
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China BPH Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Treatment
8.3.1.2.2. By Surgical Treatment
8.3.1.2.3. By End User
8.3.2. Japan BPH Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Treatment
8.3.2.2.2. By Surgical Treatment
8.3.2.2.3. By End User
8.3.3. India BPH Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Treatment
8.3.3.2.2. By Surgical Treatment
8.3.3.2.3. By End User
8.3.4. South Korea BPH Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Treatment
8.3.4.2.2. By Surgical Treatment
8.3.4.2.3. By End User
8.3.5. Australia BPH Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Treatment
8.3.5.2.2. By Surgical Treatment
8.3.5.2.3. By End User
9. SOUTH AMERICA BPH TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Treatment
9.2.2. By Surgical Treatment
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil BPH Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Treatment
9.3.1.2.2. By Surgical Treatment
9.3.1.2.3. By End User
9.3.2. Argentina BPH Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Treatment
9.3.2.2.2. By Surgical Treatment
9.3.2.2.3. By End User
9.3.3. Colombia BPH Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Treatment
9.3.3.2.2. By Surgical Treatment
9.3.3.2.3. By End User
10. MIDDLE EAST AND AFRICA BPH TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Treatment
10.2.2. By Surgical Treatment
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. UAE BPH Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Treatment
10.3.1.2.2. By Surgical Treatment
10.3.1.2.3. By End User
10.3.2. Saudi Arabia BPH Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Treatment
10.3.2.2.2. By Surgical Treatment
10.3.2.2.3. By End User
10.3.3. South Africa BPH Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Treatment
10.3.3.2.2. By Surgical Treatment
10.3.3.2.3. By End User
10.3.4. Turkey BPH Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Drug Treatment
10.3.4.2.2. By Surgical Treatment
10.3.4.2.3. By End User
10.3.5. Egypt BPH Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Drug Treatment
10.3.5.2.2. By Surgical Treatment
10.3.5.2.3. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.1.1. Increasing prevalence of Benign Prostate Hyperplasia
11.1.2. Growing geriatric population
11.1.3. Technological Advancement
11.2. Challenges
11.2.1. High Cost of Procedure
11.2.2. Side effects associated with the technique
11.2.3. Lack of Skilled Professionals to conduct invasive surgeries
12. MARKET TRENDS & DEVELOPMENTS
12.1. Development of new drugs
12.2. Development of new surgeries
13. CLINICAL TRIAL ANALYSIS
13.1. Ongoing Clinical Trials
13.2. Completed Clinical Trials
13.3. Terminated Clinical Trials
13.4. Breakdown of Pipeline, By Development Phase
13.5. Breakdown of Pipeline, By Status
13.6. Breakdown of Pipeline, By Study Type
13.7. Breakdown of Pipeline, By Region
13.8. Clinical Trials Heat Map
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (In Case of Listed Companies)
14.5. Key Personnel
14.5.1. Boston Scientific Corporation
14.5.2. Coloplast Corporation
14.5.3. Teleflex Incorporated
14.5.4. Olympus Corporation
14.5.5. Glaxo Smith Kline PLC
14.5.6. Eli Lily
14.5.7. Abott Laboratories
14.5.8. Medifocus Inc.
14.5.9. Urologix, LLC
14.5.10. Pfizer Inc
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US AND DISCLAIMER
